Parenteral Nutrition Market Share

North America Market Insights

North America in the parenteral nutrition market is anticipated to garner the largest share of 42.3% by the end of 2035. The market’s growth in the overall region is propelled by a rise in chronic disorders, increased shift from inpatient to remote parenteral nutrition, the presence of CMS reimbursement policies, and the aspect of reduced health and medical expenses. According to an article published by NLM in January 2024, the approximate expense of chronic disease is over USD 1 trillion in the regional medical system. Besides, these diseases cater to an overwhelming disability and death percentage in the U.S., which is positively impacting the market.

The parenteral nutrition market in the U.S. is significantly growing, owing to an increase in remote services, which is readily driven by the existence of CMS policies that focus on affordable site-of-care transitions. In addition, the support provision by Medicare coverage for nutrients and infusion pumps is also driving the market in the country. As stated in the June 2025 Office of Inspector General article, as of 2022 and 2023, Medicare paid over USD 487 million for parenteral nutrition under the Social Security Act of 1861 (s)(8), as well as 1862 (a)(1)(A). Besides, the NIH has highlighted in-depth research to support SMOFlipid-based emulsions in the country to diminish PNALD, thus suitable for the market’s development.

The parenteral nutrition market in Canada is also growing due to the presence of provincial health and medical systems, which are readily focused on expanding accessibility and standardizing care outside acute environments. In addition, the implementation and development of provincial HPN programs, suitable to optimize patient life quality and manage expenses, is also boosting the market in the country. Besides, the Nutritional International Organization, in one of its February 2025 articles, noted that the Government of Canada initiated an investment of USD 360.6 million. The purpose is to significantly provide support to high and impactful nutrition programming for the upcoming 6 years, and improve health, generate economic and educational outcomes, and save lives in more than 60 nations.

Chronic Disease Prevalence in North America (2024)

Source: CDC

APAC Market Insights

The Asia Pacific in the parenteral nutrition market is expected to emerge as the fastest-growing region during the forecast period. The market’s development in the region is highly driven by an upsurge in the aging population, especially in South Korea and Japan, an increase in disposable income, and huge government investments in health facilities, particularly in India and China. According to an article published by the UNESCAP Organization in 2022, 1 in 7 people in Asia and the Asia Pacific are aged more than 60 years, and by the end of 2050, 1 in 4 people is predicted to belong to this particular age category. Therefore, there is a massive chance for this particular group to be affected by rare diseases, hence denoting a growth opportunity for the market.

The parenteral nutrition market in China is gaining increased traction, owing to the existence and generous contributions by the National Medical Products Administration (NMPA), and an upsurge in patients aided with parenteral nutrition-based treatments. This is highly fueled by an increase in gastric cancer incidence, along with optimization in accessibility across tier-2/3 cities. According to an article published by NLM in April 2025, the country caters to 70% of cardia and 50% of non-cardia gastric cancer. In addition, the disease in the country originates from a convergence of behavioral and biological drivers, thus uplifting the market’s demand.

The parenteral nutrition market in India is also developing due to the presence of immense support, which is provided through government healthcare strategies. In this regard, Ayushman Bharat has successfully facilitated a surge in patients effectively accessing parenteral nutrition, with the majority of patients receiving standard treatment. As per the July 2024 PIB article, the Central Pool in the country accounts for 608.7 lakh metric tons of food grains, which significantly surpasses the 411.2 lakh metric ton stocking norm. Besides, the National Food Security Act has entitled almost 75% of the rural population, as well as 50% of the urban population, thus creating an optimistic outlook for the overall market.

Living Arrangements for the Older Population in Asia and the Asia Pacific (2022)

Source: UNESCAP Organization

Europe Market Insights

Europe in the parenteral nutrition market is projected to grow steadily by the end of the forecast period. The market’s growth in the region is highly determined by high standards of clinical care, an increase in the elderly population, strong public healthcare and medical systems, and strict administrative oversight by the EMA. Additionally, the tactical shift from hospital-based compounded bags to standardized and ready-to-use multi-chamber bags is also bolstering the market by reducing medication errors and healthcare expenses. Moreover, there is a strong push for incorporating advanced lipid emulsions, including SMOFlipid to combat parenteral nutrition-associated liver disease, thus denoting a positive impact for the overall market in the region.

The parenteral nutrition market in Germany is gaining increased exposure, owing to a surge in medical spending, with the Federal Ministry of Health reporting a growth in demand. This is effectively attributed to wide-ranging insurance coverage, as well as healthcare infrastructure. According to the 2025 Germany Visa Organization data report, the healthcare expenditure in the country accounted for 474.1 billion euros, with life expectancy in the country catering to 83.3 years for women and 78.5 years for men, thereby suitable for uplifting the overall market.

The parenteral nutrition market in France is also growing, due to tactical governmental strategies to enhance efficacy in its national health system. In addition, the French National Authority for Health (HAS) has integrated reforms that strongly focus on ready-to-use parenteral formulations, along with home-based care to diminish hospital admission rates and related expenses. Besides, the Ministry of Solidarity and Health has displayed a continuous yearly increase in HPN patients, readily backed by the presence of a standard reimbursement system that can facilitate accessibility to innovative nutrition support.